After a few minutes of eyestrain, I was able to locate a Web version of the story, with a different headline. It dates to 1993:
A fifth volunteer died Tuesday from an experimental drug touted as a miracle cure for hepatitis B, beyond medical rescue even as scientists unraveled the mystery of what went gravely wrong in a clinical trial.
Researchers at the National Institutes of Health have agonized over the fact that the first clue was in sight a year ago, but they didn’t know enough about how the drug worked to recognize what it meant, the study’s lead scientist says.
And he wasn’t kidding, either:
The drug, Fialuridine, or FIAU, had shown great promise for fighting the hepatitis B virus, which can cause deadly cirrhosis and liver cancer. When animals passed toxicity tests unharmed, the Food and Drug Administration approved FIAU for human trials.
Too late, scientists would discover that in humans, FIAU stealthily attacks the very building blocks of cells in livers, kidneys and nerves.
Two decades later, there are some drugs that actually seem to help.